In the News
Six drugs that could change the world
The strength of the state’s world-class drug developers is usually measured in terms of jobs and economics, rather than the effect on human health in coming [...]
Startup Finds Hope in Second Look at “Failed” Alzheimer’s Drugs
Alzheon will first take a closer look at a drug designed to target the brain-damaging amyloid plaques that are the hallmarks of Alzheimer’s. In the hands [...]
Alzheimer’s team tackles a daunting R&D field with a new game plan
The drug is tramiprosate, which flunked a big study back in 2009. It's been rebuilt, so to speak, so it can be delivered through the gut [...]
Alzheon Emerges From Stealth, Hunts for Alzheimer’s Castoffs
Clinical trial flops have become the norm for Alzheimer’s disease treatments, despite the billions put into research for the memory-robbing disorder. But a new Lexington, MA-based [...]
Press Releases
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials.
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
Study to Evaluate ALZ-801 Effects on Alzheimer’s Biomarkers Associated with Clinical BenefitIncludes Comprehensive Biomarker Assessment to Accelerate Development of ALZ-801 for Alzheimer’s Disease PreventionFacilitates Biomarker-Enabled Indication Expansion [...]
Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease
Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic ProfileGrant Supports Advancement of the First Oral Agent with [...]
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker ResultsSelectivity for Amyloid [...]
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]